What happens to appetite when you stop

The common expectation is that stopping flips a switch — the last injection wears off and hunger arrives. That is not how it works, and the difference matters for planning.

These medicines leave the body slowly by design. Both are engineered to bind to albumin in the blood, which protects them from being broken down and cleared, and that is what makes a weekly injection possible in the first place. The same property means the effect fades over weeks rather than days.

So what people describe is not a sudden return of hunger but a slow loosening: portions creeping up, the sense of fullness arriving later in a meal, then eventually not arriving when expected.

Half-life is the time taken for the concentration in the blood to fall by half, and a medicine is generally considered effectively cleared after about five half-lives. Both figures are published.

This is worth noticing because it turns three separate pieces of advice into one mechanism.

It explains the pre-conception wash-out. The MHRA advises stopping at least two months before trying to conceive for semaglutide and at least one month for tirzepatide — the ratio follows the half-lives rather than being an arbitrary pair of numbers.

And it explains the shape of the regain seen in trials. In the STEP 1 extension, participants regained around two-thirds of the weight they had lost over the year after stopping, which is a curve rather than a step, and the first part of that curve is the drug declining rather than anything behavioural.

Many people describe two distinct effects while on treatment: physical fullness arriving sooner in a meal, and a quieting of the constant low-level awareness of food — the thing commonly called food noise.

Those two do not fade together. The reported pattern is that the mental component returns earlier, often within two to three weeks of the last injection, while the physical fullness holds on somewhat longer.

That ordering is unhelpful. It produces a window in which the preoccupation with food has come back but the capacity to eat large portions has not yet fully returned — which is uncomfortable and easy to read as a personal failure when it is a pharmacological sequence.

This is the practical conclusion, and it is the opposite of how most people plan.

The instinct is to treat the last injection as the start of the work: stop the medicine, then build the habits that replace it. The arithmetic says the opposite. The weeks either side of stopping are the ones where appetite is still partly suppressed, so they are the cheapest weeks in which to establish a way of eating — a protein target, a meal structure, a shopping pattern — that has to hold once the suppression has gone entirely.

A habit built while the medicine is still doing some of the work is a habit that already exists when it stops. A habit attempted from scratch at full appetite is a different and much harder exercise.

That is also why our maintenance guidance treats the phase as its own piece of work rather than as an epilogue.

Expect portions to grow before you notice hunger returning. Expect the change to be gradual enough that you may not see it week to week, which is an argument for keeping the same weekly record you kept during treatment.

Expect some weight regain. It is the common outcome rather than a sign anything has gone wrong, and the honest framing is that these treatments manage a condition rather than cure it.

Worth raising with a prescriber: appetite returning much faster or more intensely than this describes, weight climbing quickly in the first few weeks, or the return of binge patterns that treatment had interrupted. The last of those in particular is a clinical conversation rather than a willpower one.